The share issue is directed to selected international specialist investors as well as Swedish institutional and strategic investors. The issue proceeds will primarily be used to finance the development process of the drug candidate IdeS up to an application for market authorization of IdeS for treatment in connection with kidney transplantation. The share issue is fully subscribed for in accordance with agreements executed with the selected investors. Shareholders representing approximately 45 percent of Hansa Medical’s shares and votes have undertaken to vote in favor of the board’s proposal for the share issue at an extraordinary general meeting.
Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. The company’s shares are admitted to trading on Nasdaq Stockholm.
Vinge’s team consists of Dain Hård Nevonen, Erik Sjöman and Nils Fredrik Dehlin.
